PHARMACY | GENERICS
agreement with an undisclosed pharmaceutical partner to market and distribute some select ophthalmic and otic abbreviated new drug application products. In 2019, UpsherSmith also added two newly acquired, FDAapproved sumatriptan products to its branded central nervous system. “The products are an excellent fit with our current [central nervous system] portfolio, and bring new dosage forms with their intranasal and injectable delivery, while also diversifying our portfolio beyond ANDA products,” Field said. “Upsher-Smith plans to strategically pursue acquisitions of generic and targeted brand opportunities that leverage our team’s commercial capabilities in both segments of the prescription drug market.” As more generics companies diversify their portfolios going forward, several executives said that by doing so they are ensuring that their customers have a steady
DEDICATED TO QUALITY & SUPPLY...
60
February 2020 DRUGSTORENEWS.COM